NewslettersCell Therapy NewsMuscle Cell NewsCapricor Therapeutics Announces First Patient Dosed in Pivotal Phase III Study of CAP-1002 for the Treatment of Duchenne Muscular DystrophyBy lbeveridge - July 25, 20220379Capricor Therapeutics announced commencement of dosing in HOPE-3, a Phase III clinical trial investigating CAP-1002, a cell therapy for treating late-stage Duchenne muscular dystrophy[Capricor Therapeutics]Graphical Abstract